Press Releases

 
Press Releases
  Date Title View
Oct 13, 2017
CAMBRIDGE, Mass., Oct. 13, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) (the "Company" or "Merrimack") today announced that it has commenced a tender offer (the "Tender Offer") to purchase any and all of its $25,031,000 aggregate principal amount of outstanding 4.50% Convertible Senior Notes due 2020 (CUSIP No. 590328AA8; ISIN No. ...
Oct 10, 2017
CAMBRIDGE, Mass., Oct. 10, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that it has reached a settlement agreement with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, "Noteholder Plaintiffs") and Wells Fargo Bank, National Association, t...
Aug 31, 2017
CAMBRIDGE, Mass., Aug. 31, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that the previously disclosed one-for-ten reverse stock split of its issued and outstanding common stock will be effective for trading purposes as of the commencement of trading on September 6, 2017. Merrimack's stockholders approved an amendmen...
Aug 14, 2017
CAMBRIDGE, Mass., Aug. 14, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that it has strengthened its executive management team with the appointment of Jean M. Franchi as Chief Financial Officer, effective August 21, 2017. In this role, Ms. Franchi will plan and oversee Merrimack's financial strategy to support the o...
Aug 9, 2017
CAMBRIDGE, Mass., Aug. 9, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its second quarter 2017 financial results for the period ended June 30, 2017. "This quarter's progress, with key hires to the executive team and advancements in the clinic, has reinforced Merrimack's refined corporate and clinical s...
Aug 2, 2017
CAMBRIDGE, Mass., Aug. 2, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its second quarter 2017 investor conference call and webcast at 8:30 am ET on Wednesday, August 9, 2017.   The call will cover an update on Merrimack's recent progress as well as a summary of second quarter...
Jul 24, 2017
CAMBRIDGE, Mass., July 24, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced  further expansion of its executive management team with the appointment of Thomas E. Needham, Jr., M.B.A., to the position of Chief Business Officer. In this role, Mr. Needham will help design and implement Merrimack's strategy for its broad pi...
Jun 19, 2017
CAMBRIDGE, Mass., June 19, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that it has enrolled the last patient in the ongoing CARRIE study, a Phase 2, double-blind, placebo-controlled, randomized trial, evaluating MM-141 (istiratumab) in combination with standard of care in previously untreated patients with me...
Jun 8, 2017
CAMBRIDGE, Mass., June 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the expansion of its senior management team through the addition of two new executive hires. Sergio L. Santillana, M.D., MSc, a medical oncologist with extensive industry experience leading a wide range of clinical development programs, has...
May 25, 2017
CAMBRIDGE, Mass., May 25, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the resignation of Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development, effective June 9, 2017. Dr. Al-Wakeel, who has been in his role with Merrimack since August 2015, is leaving to pursue other business inter...
1
...
NextLast
= add release to Briefcase

In this section, you will find several of Merrimack’s high-resolution images. All images here are copyrighted by Merrimack Pharmaceuticals, Inc., and are made available here for editorial use only. By downloading and/or using any of the Merrimack’s images, you acknowledge the rights of Merrimack’s images, and you agree to comply with the usage guidelines.

X

Accept | Decline